Glaucoma Inhibition of Monocyte Chemoattractant Protein 1 Prevents Conjunctival Fibrosis in an Experimental Model of Glaucoma Filtration Surgery

Citation: Chong RS, Lee YS, Chu SWL, Toh LZ, Wong TTL. Inhibition of monocyte chemoattractant protein 1 prevents conjunctival fibrosis in an experimental model of glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2017;58:3432–3439. DOI: 10.1167/iovs.17-21480 PURPOSE. To evaluate the effect of treatment with monocyte chemoattractant protein-1 receptor inhibitor (MCP-Ri) to maintain bleb survival and prevent fibrosis in an experimental model of glaucoma filtration surgery (GFS). METHODS. GFS was performed on one eye of C57/Bl6 mice (n 1⁄4 36) that was treated with MCP-Ri, mitomycin-C (MMC), or vehicle at the time of surgery. Real-time polymerase chain reaction was used to evaluate conjunctival expression of monocyte chemoattractant protein-1 (MCP-1), TGFB1, TGFB2, collagen 1a1 (Col1a1), sparc (Sparc), and fibronectin at 2 and 7 days following surgery. Anterior segment slit-lamp examination, optical coherence tomography, and confocal microscopy were performed in vivo at day 14. Eyes were processed for immunohistochemical staining of F4/80, a monocyte–macrophage marker, at day 2. In vitro experiments were also performed to compare the effect of MMC, MCP-Ri, and vehicle on the viability of mouse Tenon’s fibroblasts.